Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Advance Paradigm Lescol and Pravachol switch programs help agents gain market share.

Executive Summary

ADVANCE PARADIGM LESCOL, PRAVACHOL SWITH PROGRAM has helped the two newer cholesterol-lowering agents gain market share at an IPA-model HMO, although Merck's Zocor continues to hold the number one position, according to a poster presentation at the Academy of Managed Care Pharmacy meeting in Orlando Nov. 1. Advance Paradigm began a test of the switch program in March at a 60,000 patient IPA-model HMO. The market share for Sandoz' Lescol (fluvastatin) increased from 19.5% to 24.9%, while Bristol-Myers Squibb's Pravachol (pravastatin) moved from a 17.9% share to 22.4%. Zocor (simvastatin) saw its market share drop from 40% to 34.6%, while Merck's Mevacor (lovastatin) fell from a 25.7% share to 18.1%.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

PS078529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel